AGARWALEYE
Dr. Agarwal's Health Care Limited operates eye hospitals in India and internationally. It offers cataract surgeries, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery, and glued intraocular lens treatments; and refractive surgeries, including surgical procedures to correct the refractive error of the eye to get rid of or reduce dependence on glasses and contac… Read more
AGARWALEYE (AGARWALEYE) - Net Assets
Latest net assets as of September 2025: ₹20.19 Billion INR
Based on the latest financial reports, AGARWALEYE (AGARWALEYE) has net assets worth ₹20.19 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹37.86 Billion) and total liabilities (₹17.67 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹20.19 Billion |
| % of Total Assets | 53.32% |
| Annual Growth Rate | 76.47% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 64.75 |
AGARWALEYE - Net Assets Trend (2021–2025)
This chart illustrates how AGARWALEYE's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AGARWALEYE (2021–2025)
The table below shows the annual net assets of AGARWALEYE from 2021 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹19.27 Billion | +38.31% |
| 2024-03-31 | ₹13.93 Billion | +111.38% |
| 2023-03-31 | ₹6.59 Billion | +181.87% |
| 2022-03-31 | ₹2.34 Billion | +17.68% |
| 2021-03-31 | ₹1.99 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to AGARWALEYE's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 44150200000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₹315.90 Million | 1.69% |
| Other Comprehensive Income | ₹-329.10 Million | -1.76% |
| Other Components | ₹20.51 Billion | 109.89% |
| Total Equity | ₹18.67 Billion | 100.00% |
AGARWALEYE Competitors by Market Cap
The table below lists competitors of AGARWALEYE ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ENDUR ASA NK 050
F:4ZT0
|
$295.15 Million |
|
GMR Power and Urban Infra Limited
NSE:GMRP&UI
|
$295.15 Million |
|
FastPartner AB Series D
ST:FPAR-D
|
$295.16 Million |
|
Nowtransit Inc
PINK:NOTR
|
$295.18 Million |
|
Xinlei Compressor Co. Ltd. A
SHE:301317
|
$295.02 Million |
|
Telecom Argentina S.A
PINK:TCMFF
|
$295.01 Million |
|
DongKook Pharmaceutical Co. Ltd
KQ:086450
|
$294.94 Million |
|
Inst Diagnosti
SN:INDISA
|
$294.91 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AGARWALEYE's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 13,476,370,000 to 18,665,900,000, a change of 5,189,530,000 (38.5%).
- Net income of 834,600,000 contributed positively to equity growth.
- Dividend payments of 7,900,000 reduced retained earnings.
- New share issuances of 6,595,000,000 increased equity.
- Other comprehensive income decreased equity by 329,100,000.
- Other factors decreased equity by 1,903,070,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹834.60 Million | +4.47% |
| Dividends Paid | ₹7.90 Million | -0.04% |
| Share Issuances | ₹6.59 Billion | +35.33% |
| Other Comprehensive Income | ₹-329.10 Million | -1.76% |
| Other Changes | ₹-1.90 Billion | -10.2% |
| Total Change | ₹- | 38.51% |
Book Value vs Market Value Analysis
This analysis compares AGARWALEYE's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.86x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 71.16x to 6.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-03-31 | ₹5.99 | ₹426.25 | x |
| 2022-03-31 | ₹6.91 | ₹426.25 | x |
| 2023-03-31 | ₹20.47 | ₹426.25 | x |
| 2024-03-31 | ₹43.82 | ₹426.25 | x |
| 2025-03-31 | ₹62.13 | ₹426.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AGARWALEYE utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.88%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.97x
- Recent ROE (4.47%) is above the historical average (2.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -30.11% | -11.77% | 0.60x | 4.27x | ₹-739.02 Million |
| 2022 | 17.75% | 5.42% | 0.68x | 4.83x | ₹164.56 Million |
| 2023 | 14.95% | 9.26% | 0.56x | 2.90x | ₹311.41 Million |
| 2024 | 7.55% | 7.63% | 0.48x | 2.06x | ₹-330.74 Million |
| 2025 | 4.47% | 4.88% | 0.47x | 1.97x | ₹-1.03 Billion |
Industry Comparison
This section compares AGARWALEYE's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,790,564,333
- Average return on equity (ROE) among peers: 8.64%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AGARWALEYE (AGARWALEYE) | ₹20.19 Billion | -30.11% | 0.88x | $295.11 Million |
| LAXMIDENTL (LAXMIDENTL) | $194.82 Million | -20.39% | 3.96x | $18.92K |
| Poly Medicure Limited (POLYMED) | $278.57 Million | 25.76% | 1.06x | $481.09 Million |
| Tarsons Products Limited (TARSONS) | $4.90 Billion | 20.55% | 0.11x | $22.74 Million |